In a landmark announcement, the World Health Organization (WHO) has recommended the use of the first-ever malaria vaccine for children. WHO Director-General Tedros Adhanom Ghebreyesus endorsed the RTS,S/AS01 malaria or Mosquirix – a vaccine developed by British drugmaker GlaxoSmithKline (GSK).

The WHO has recommended extensive use of the RTS,S/AS01  vaccine among children in Sub-Saharan Africa and other regions with moderate to high malaria transmission. The vaccine acts against the deadliest malaria transmission parasite, P. falciparum, which is prevalent in Africa. The symptoms of malaria are–fever, headaches, and muscle pain, then cycles of chills, fever, and sweating.

According to Tedros, ” RTS,S malaria vaccine – more than 30 years in the making – changes the course of public health history. This vaccine is a gift to the world”.

The WHO said in a statement it was recommending the widespread application of the vaccine among children in sub-Saharan Africa and other regions with moderate to high malaria transmission.

Many vaccines exist against viruses and bacteria, but this was the first time that the WHO recommended broad use of a vaccine against a human parasite.

According to the latest World Malaria Report, there were an estimated 229 million cases of malaria globally in 2019, with the WHO African region accounting for 94 per cent of all cases and deaths.

A child under five years old dies of malaria every two minutes, according to UNICEF estimates, while WHO says that malaria is responsible for 260,000 deaths each year in children under five in Africa.

The third phase of clinical trials revealed that the vaccine was 50 per cent efficacious in preventing malaria in children aged between five and 17 months. The vaccine is given in three doses between these ages, with a fourth dose about 18 months later.

According to Reuters news agency, experts said the challenge now would be mobilising financing for production and distribution of the vaccine. GSK has to date committed to producing 15 million doses of Mosquirix annually up to 2028 at a cost of production plus no more than 5% margin.

A global market study led by the WHO this year projected demand for a malaria vaccine would be 50 to 110 million doses per year by 2030 if it is deployed in areas with moderate to high transmission of the disease.

Resources:
https://www.livemint.com/science/health/who-approves-world-s-first-malaria-vaccine-11633573233450.html

More News
Containers pile up in Shanghai port on China’s COVID lockdowns
News · 02/05/2022

The strictest COVID -19 lockdown in China since the pandemic began has resulted in container goods sitting at Shanghai’s port for nearly two weeks.

READ MORE
Could cyber-physical watermarks be the key to pill-level traceability?
News · 01/04/2022

New anti-counterfeit technology, called a cyber-physical watermark, leverages edible fluorescent silk to identify medications.

READ MORE
World economy faces supply hit as China battles Covid
News · 01/04/2022

The global economy — already struggling with war in Ukraine and the stagflation risks it’s fanning — is bracing for greater disruption as China scrambles to contain its worst outbreak of Covid-19 since the pandemic began.

READ MORE
Impact of Oil hitting a seven-year high on world economy
News · 02/03/2022

Oil prices surged past $100 (£74) a barrel to hit their highest level for more than seven years after Russia launched an invasion of Ukraine.

READ MORE
What’s at Stake for the Global Economy as Conflict Looms in Ukraine?
News · 02/03/2022

The Russian invasion of Ukraine is already dealing a blow to financial markets and the worldwide economy. Global supply chains and growth had been broadly recovering from the pandemic, but now all that’s in doubt, given the stricter sanctions and other punitive measures against Russia that are in the offing.

READ MORE
2022 | How the pharma industry is shaping up for the future
News · 17/01/2022

Given the evolving on-ground situation and newer variant-led infections, the pandemic is far from over. In such a scenario, for businesses to stay relevant, we will need to be flexible and more adaptable to the changes that need to be embraced to keep core business growth drivers resilient.

READ MORE
2022 | Chemical & Renewable Energy Industry Outlook
News · 06/12/2021

As the chemical industry moves into 2022, strong demand for both commodity and specialty chemicals should keep prices robust throughout the year. The industry could face margin pressures amid raw material cost inflation, which will likely remain high through the first half of 2022.

READ MORE
China’s strategic power cuts & “green” Winter Olympics 2022
News · 05/12/2021

Blackouts and power cuts in the world’s second-largest economy have drawn attention to fuel supply problems that could complicate the country’s pandemic recovery.

READ MORE
FIEO urges govt to provide freight support to all exports including pharmaceuticals till March 2022
News · 22/11/2021

The Federation of Indian Export Organizations (FIEO), an apex body of Indian export promotion organizations, has urged the government to provide freight support to all exports including pharmaceuticals till 31st March 2022, as freight rates have skyrocketed and are likely to somber by March 2022.

READ MORE